Biocryst Pharma Inc (BCRX) 3.09 $BCRX
BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Hemorrhagic Fever Virus Diseases
GlobeNewswire - Tue Jul 05, 6:30AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has provided additional funding for efficacy studies of BCX4430 in non-human primates to further assess effective dose regimens.
BCRX: 3.09 (+0.10)
Technical Coverage of Biotechnology Stocks - Agenus, BioCryst Pharma, Cempra, and Hemispherx Biopharma
PR Newswire - Thu Jun 30, 7:40AM CDT
On Wednesday, June 29, 2016, the NASDAQ Composite ended the trading session at 4,779.25, up 1.86%; the Dow Jones Industrial Average advanced 1.64%, to finish at 17,694.68; and the S&P 500 closed at 2,070.77, up 1.70%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Agenus Inc. (NASDAQ: AGEN), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Cempra Inc. (NASDAQ: CEMP), and Hemispherx Biopharma Inc. (NYSEMKT: HEB). Learn more about these stocks by accessing their free trade alerts at:
AGEN: 4.79 (+0.10), BCRX: 3.09 (+0.10), HEB: 0.11 (unch), CEMP: 17.98 (+0.17)
BioCryst to Present at Two Upcoming Investor Conferences
GlobeNewswire - Thu May 26, 7:55AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at the following investor conferences:
BCRX: 3.09 (+0.10)
BioCryst Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 5:44AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the first quarter ended March 31, 2016.
BCRX: 3.09 (+0.10)
BioCryst to Announce First Quarter 2016 Financial Results May 5
GlobeNewswire - Thu Apr 21, 5:48AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2016 financial results will be released on Thursday, May 5, 2016. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update regarding the Company's clinical development programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Thomas R. Staab, II, Senior Vice President and Chief Financial Officer and Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer.
BCRX: 3.09 (+0.10)
BioCryst to Present at Barclays Healthcare Conference
GlobeNewswire - Wed Mar 09, 8:29AM CST
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's development programs at the Barclays Healthcare Conference in Miami, FL on Thursday, March 17, 2016 at 1:05 pm. Eastern Time.
BCRX: 3.09 (+0.10)
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Up 15.5%
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 7:15AM CST
BioCryst Pharmaceuticals, Inc. (BCRX) shares rose almost 16% in the last trading session.
BCRX: 3.09 (+0.10), EARS: 4.09 (+0.06)
Traders Get Bullish on Shares of BioCryst Pharmaceuticals, Shares Up 18.8% (BCRX)
Comtex SmarTrend(R) - Mon Mar 07, 10:18AM CST
BioCryst Pharmaceuticals (NASDAQ:BCRX) is one of today's best performing low-priced stocks, up 18.8% to $3.07 on 1.5x average daily volume. BioCryst Pharmaceuticals has traded 2.8 million shares thus far today, vs. average volume of 1.9 million shares per day. The stock has outperformed the Dow (18.8% to the Dow's 0.1%) and outperformed the S&P 500 (18.8% to the S&P's -0.2%) during today's trading.
BCRX: 3.09 (+0.10)
Study Results From Zika Virus Infected Mice Treated With BCX4430 to be Presented at WHO Conference
GlobeNewswire - Mon Mar 07, 5:45AM CST
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that results from a preclinical study of its broad spectrum antiviral BCX4430 in immune-deficient mice infected with Zika virus will be presented at a World Health Organization (WHO) meeting scheduled to take place March 7-9 in Geneva, Switzerland.
BCRX: 3.09 (+0.10)
Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma
Arpita Dutt - Zacks Investment Research - Wed Feb 10, 10:02AM CST
Disappointing pipeline and regulatory updates from companies like CTI BioPharma (CTIC) and Sarepta (SRPT) and earnings misses from Alexion and Regeneron were the highlights this week.
BCRX: 3.09 (+0.10), VRTX: 88.96 (-1.09), GILD: 86.55 (+1.08), SRPT: 22.62 (+1.70), ALXN: 124.42 (+1.08), CTIC: 0.35 (-0.01), REGN: 378.35 (+6.90)
BioCryst Pharmaceuticals (BCRX) in Focus: Stock Jumps 6.2%
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:35AM CST
BioCryst Pharmaceuticals, Inc. (BCRX) was a big mover last session, as the company saw its shares rise over 6% on the day.
BCRX: 3.09 (+0.10), PETX: 7.00 (+0.31)
Company News for February 09, 2016
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 9:10AM CST
Companies in the News are; HAS,DO,CNA,BCRX
HAS: 84.71 (+1.60), BCRX: 3.09 (+0.10), DO: 24.50 (+0.48), CNA: 31.45 (-0.18)
Downgrade Alert for BioCryst Pharmaceuticals (BCRX)
Comtex SmarTrend(R) - Tue Feb 09, 8:11AM CST
BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded from Buy to Hold at Jefferies today. The stock closed yesterday at $1.78 on volume of 9.3 million shares, above average daily volume of 761,000. BioCryst Pharmaceuticals (NASDAQ:BCRX) has potential upside of 812.9% based on a current price of $1.78 and analysts' consensus price target of $16.25. The stock should find initial resistance at its 50-day moving average (MA) of $8.86 and further resistance at its 200-day MA of $11.16.
BCRX: 3.09 (+0.10)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of BioCryst Pharmaceuticals, Inc. -- BCRX
BusinessWire - Mon Feb 08, 11:04AM CST
Levi & Korsinsky announces it has commenced an investigation of BioCryst Pharmaceuticals, Inc. (NASDAQGS: BCRX) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
BCRX: 3.09 (+0.10)
Shares of BCRX Down 20.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 05, 10:49AM CST
SmarTrend identified a Downtrend for BioCryst Pharmaceuticals (NASDAQ:BCRX) on January 11th, 2016 at $8.23. In approximately 4 weeks, BioCryst Pharmaceuticals has returned 20.91% as of today's recent price of $6.51.
BCRX: 3.09 (+0.10)
BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Hemorrhagic Fever Virus Diseases
GlobeNewswire - Tue Jul 05, 6:30AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has provided additional funding for efficacy studies of BCX4430 in non-human primates to further assess effective dose regimens.
BCRX: 3.09 (+0.10)
Technical Coverage of Biotechnology Stocks - Agenus, BioCryst Pharma, Cempra, and Hemispherx Biopharma
PR Newswire - Thu Jun 30, 7:40AM CDT
On Wednesday, June 29, 2016, the NASDAQ Composite ended the trading session at 4,779.25, up 1.86%; the Dow Jones Industrial Average advanced 1.64%, to finish at 17,694.68; and the S&P 500 closed at 2,070.77, up 1.70%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Agenus Inc. (NASDAQ: AGEN), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Cempra Inc. (NASDAQ: CEMP), and Hemispherx Biopharma Inc. (NYSEMKT: HEB). Learn more about these stocks by accessing their free trade alerts at:
AGEN: 4.79 (+0.10), BCRX: 3.09 (+0.10), HEB: 0.11 (unch), CEMP: 17.98 (+0.17)
BioCryst to Present at Two Upcoming Investor Conferences
GlobeNewswire - Thu May 26, 7:55AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at the following investor conferences:
BCRX: 3.09 (+0.10)
BioCryst Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 5:44AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the first quarter ended March 31, 2016.
BCRX: 3.09 (+0.10)
BioCryst to Announce First Quarter 2016 Financial Results May 5
GlobeNewswire - Thu Apr 21, 5:48AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2016 financial results will be released on Thursday, May 5, 2016. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update regarding the Company's clinical development programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Thomas R. Staab, II, Senior Vice President and Chief Financial Officer and Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer.
BCRX: 3.09 (+0.10)
BioCryst to Present at Barclays Healthcare Conference
GlobeNewswire - Wed Mar 09, 8:29AM CST
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's development programs at the Barclays Healthcare Conference in Miami, FL on Thursday, March 17, 2016 at 1:05 pm. Eastern Time.
BCRX: 3.09 (+0.10)
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Up 15.5%
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 7:15AM CST
BioCryst Pharmaceuticals, Inc. (BCRX) shares rose almost 16% in the last trading session.
BCRX: 3.09 (+0.10), EARS: 4.09 (+0.06)
Traders Get Bullish on Shares of BioCryst Pharmaceuticals, Shares Up 18.8% (BCRX)
Comtex SmarTrend(R) - Mon Mar 07, 10:18AM CST
BioCryst Pharmaceuticals (NASDAQ:BCRX) is one of today's best performing low-priced stocks, up 18.8% to $3.07 on 1.5x average daily volume. BioCryst Pharmaceuticals has traded 2.8 million shares thus far today, vs. average volume of 1.9 million shares per day. The stock has outperformed the Dow (18.8% to the Dow's 0.1%) and outperformed the S&P 500 (18.8% to the S&P's -0.2%) during today's trading.
BCRX: 3.09 (+0.10)
Study Results From Zika Virus Infected Mice Treated With BCX4430 to be Presented at WHO Conference
GlobeNewswire - Mon Mar 07, 5:45AM CST
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that results from a preclinical study of its broad spectrum antiviral BCX4430 in immune-deficient mice infected with Zika virus will be presented at a World Health Organization (WHO) meeting scheduled to take place March 7-9 in Geneva, Switzerland.
BCRX: 3.09 (+0.10)
Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma
Arpita Dutt - Zacks Investment Research - Wed Feb 10, 10:02AM CST
Disappointing pipeline and regulatory updates from companies like CTI BioPharma (CTIC) and Sarepta (SRPT) and earnings misses from Alexion and Regeneron were the highlights this week.
BCRX: 3.09 (+0.10), VRTX: 88.96 (-1.09), GILD: 86.55 (+1.08), SRPT: 22.62 (+1.70), ALXN: 124.42 (+1.08), CTIC: 0.35 (-0.01), REGN: 378.35 (+6.90)
BioCryst Pharmaceuticals (BCRX) in Focus: Stock Jumps 6.2%
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:35AM CST
BioCryst Pharmaceuticals, Inc. (BCRX) was a big mover last session, as the company saw its shares rise over 6% on the day.
BCRX: 3.09 (+0.10), PETX: 7.00 (+0.31)
Company News for February 09, 2016
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 9:10AM CST
Companies in the News are; HAS,DO,CNA,BCRX
HAS: 84.71 (+1.60), BCRX: 3.09 (+0.10), DO: 24.50 (+0.48), CNA: 31.45 (-0.18)
Downgrade Alert for BioCryst Pharmaceuticals (BCRX)
Comtex SmarTrend(R) - Tue Feb 09, 8:11AM CST
BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded from Buy to Hold at Jefferies today. The stock closed yesterday at $1.78 on volume of 9.3 million shares, above average daily volume of 761,000. BioCryst Pharmaceuticals (NASDAQ:BCRX) has potential upside of 812.9% based on a current price of $1.78 and analysts' consensus price target of $16.25. The stock should find initial resistance at its 50-day moving average (MA) of $8.86 and further resistance at its 200-day MA of $11.16.
BCRX: 3.09 (+0.10)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of BioCryst Pharmaceuticals, Inc. -- BCRX
BusinessWire - Mon Feb 08, 11:04AM CST
Levi & Korsinsky announces it has commenced an investigation of BioCryst Pharmaceuticals, Inc. (NASDAQGS: BCRX) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
BCRX: 3.09 (+0.10)
Shares of BCRX Down 20.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 05, 10:49AM CST
SmarTrend identified a Downtrend for BioCryst Pharmaceuticals (NASDAQ:BCRX) on January 11th, 2016 at $8.23. In approximately 4 weeks, BioCryst Pharmaceuticals has returned 20.91% as of today's recent price of $6.51.
BCRX: 3.09 (+0.10)
